X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1385) 1385
female (687) 687
male (662) 662
middle aged (627) 627
index medicus (530) 530
cryoglobulinemia (500) 500
mixed cryoglobulinemia (498) 498
adult (425) 425
cryoglobulinemia - drug therapy (405) 405
aged (383) 383
antiviral agents - therapeutic use (357) 357
hepatitis c - complications (354) 354
hepatitis c virus (353) 353
cryoglobulinemia - complications (346) 346
hepatitis c (326) 326
vasculitis (311) 311
rituximab (288) 288
treatment outcome (272) 272
hepatitis c, chronic - complications (252) 252
rheumatology (246) 246
infection (228) 228
hepatitis c, chronic - drug therapy (227) 227
interferon-alpha - therapeutic use (212) 212
cryoglobulinemia - etiology (205) 205
therapy (205) 205
gastroenterology & hepatology (198) 198
hepatitis c - drug therapy (193) 193
cryoglobulinemia - virology (189) 189
interferon (170) 170
cryoglobulinemia - diagnosis (169) 169
drug therapy, combination (165) 165
hepatitis (159) 159
hepatitis-c virus (155) 155
interferon-alpha (152) 152
cryoglobulinemia - therapy (150) 150
immunology (148) 148
medicine, general & internal (147) 147
health aspects (145) 145
glomerulonephritis (143) 143
cryoglobulinemia - immunology (136) 136
vasculitis - drug therapy (134) 134
extrahepatic manifestations (122) 122
ribavirin (122) 122
ribavirin - therapeutic use (122) 122
immunosuppressive agents - therapeutic use (120) 120
virus-infection (118) 118
urology & nephrology (117) 117
essential mixed cryoglobulinemia (116) 116
hematology (113) 113
disease (105) 105
prevalence (104) 104
antibodies, monoclonal, murine-derived (103) 103
recombinant proteins (103) 103
antibodies, monoclonal - therapeutic use (99) 99
care and treatment (98) 98
medicine & public health (98) 98
lymphoma (92) 92
membranoproliferative glomerulonephritis (92) 92
hepacivirus - genetics (91) 91
hcv (90) 90
non-hodgkins-lymphoma (90) 90
retrospective studies (88) 88
biopsy (87) 87
plasmapheresis (86) 86
cryoglobulinemia - pathology (83) 83
long-term (83) 83
vasculitis - etiology (80) 80
aged, 80 and over (79) 79
antiviral agents (78) 78
antiviral therapy (78) 78
follow-up studies (78) 78
immunologic factors - therapeutic use (78) 78
infections (78) 78
risk factors (78) 78
liver (76) 76
hepatitis c - immunology (72) 72
prognosis (72) 72
cryoglobulinemia - blood (71) 71
hcv infection (69) 69
hepatitis c, chronic - immunology (69) 69
infectious diseases (69) 69
lymphomas (69) 69
autoimmunity (67) 67
diagnosis, differential (67) 67
hepacivirus (67) 67
vasculitis - virology (67) 67
hepacivirus - immunology (66) 66
antiviral agents - administration & dosage (65) 65
drug therapy (65) 65
abridged index medicus (64) 64
cyclophosphamide - therapeutic use (64) 64
hepacivirus - isolation & purification (64) 64
ii cryoglobulinemia (64) 64
ii mixed cryoglobulinemia (63) 63
peripheral neuropathy (63) 63
glomerulonephritis, membranoproliferative - drug therapy (62) 62
randomized controlled-trial (62) 62
hepatitis c, chronic - virology (61) 61
oncology (61) 61
vasculitis - complications (60) 60
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1442) 1442
French (34) 34
Spanish (26) 26
German (21) 21
Italian (18) 18
Japanese (15) 15
Russian (14) 14
Polish (4) 4
Chinese (3) 3
Hungarian (3) 3
Danish (2) 2
Romanian (2) 2
Bulgarian (1) 1
Czech (1) 1
Hebrew (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Rheumatology, ISSN 1759-4790, 08/2016, Volume 12, Issue 8, pp. 456 - 471
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 8, pp. 2052 - 2062.e2
Background & Aims Interferon-free direct-acting antiviral (DAA) therapies are effective in patients with hepatitis C virus–induced cryoglobulinemia vasculitis... 
Gastroenterology and Hepatology | Immune Regulation | PDCD1 | Response To Treatment | Liver Disease | BAFF | ENVELOPE PROTEIN | RANDOMIZED CONTROLLED-TRIAL | MIXED CRYOGLOBULINEMIA | DEFICIENCY | AUTOIMMUNITY | RITUXIMAB | EXPANSION | REGULATORY T-CELL | GASTROENTEROLOGY & HEPATOLOGY | LYMPHOCYTES | T-Lymphocyte Subsets - immunology | Prospective Studies | Hepatitis C - drug therapy | Humans | Middle Aged | Cryoglobulinemia - diagnosis | Male | Vasculitis - virology | Cryoglobulinemia - virology | Hepatitis Viruses - drug effects | Simeprevir - therapeutic use | Case-Control Studies | Simeprevir - adverse effects | Viral Load | Vasculitis - immunology | Hepatitis C - immunology | Immunity, Cellular - drug effects | Time Factors | T-Lymphocyte Subsets - drug effects | B-Lymphocyte Subsets - immunology | Female | Hepatitis C - complications | Imidazoles - therapeutic use | Sofosbuvir - adverse effects | Drug Therapy, Combination | B-Lymphocyte Subsets - virology | Cytokines - blood | Immune Tolerance - drug effects | Sofosbuvir - therapeutic use | B-Lymphocyte Subsets - drug effects | Antiviral Agents - therapeutic use | Hepatitis Viruses - immunology | Cryoglobulinemia - drug therapy | Imidazoles - adverse effects | Ribavirin - therapeutic use | Treatment Outcome | Biomarkers - blood | T-Lymphocyte Subsets - virology | Cryoglobulinemia - immunology | Hepatitis C - diagnosis | Phenotype | B-Lymphocyte Subsets - metabolism | Vasculitis - diagnosis | Ribavirin - adverse effects | T-Lymphocyte Subsets - metabolism | Antiviral Agents - adverse effects | Vasculitis - drug therapy | Aged | Care and treatment | Vasculitis | Analysis | Gastrointestinal diseases | Interferon | Biological response modifiers | Hepatitis C virus | Antiviral agents | Medical research | Liver | Medicine, Experimental | Life Sciences | Immunology
Journal Article
Journal Article
Blood, ISSN 0006-4971, 07/2010, Volume 116, Issue 3, pp. 343 - 353
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 22, pp. 2067 - 2077
This phase 1–phase 2a study of the use of low-dose interleukin-2 to treat vasculitis associated with HCV infection suggests the presence of a therapeutic... 
MEDICINE, GENERAL & INTERNAL | HEPATITIS-C VIRUS | AUTOIMMUNITY | RITUXIMAB | EXPANSION | MIXED CRYOGLOBULINEMIA VASCULITIS | INNATE | MICE | ADAPTIVE IMMUNE-RESPONSES | CANCER | Hepacivirus - isolation & purification | Gene Expression - drug effects | Interleukin-2 - adverse effects | Humans | Middle Aged | Vasculitis - etiology | Biomarkers - analysis | Interleukin-2 - therapeutic use | Hepacivirus - genetics | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Remission Induction | T-Lymphocytes, Regulatory - immunology | Inflammation - metabolism | Inflammation - drug therapy | Interleukin-2 - administration & dosage | Vasculitis - drug therapy | Lymphocyte Count | Female | Aged | Dose-response relationship (Biochemistry) | Hepatitis viruses | Control | Interleukin-2 | Vasculitis | Physiological aspects | Dosage and administration | T cells | Drug therapy | Health aspects | Oxidative stress | Glucocorticoids | Viremia | Leukocytes (mononuclear) | Lymphocytes T | Hepatitis | Cell activation | Interleukin 2 | Acquired immune deficiency syndrome--AIDS | Peripheral blood | CD25 antigen | Foxp3 protein | Forkhead protein | Immune system | Cryoglobulinemia | Immunoregulation | Rituximab | Gene expression | Patients | CD4 antigen | Lymphocytes B | Hepatitis C | Autoimmune diseases | Liver cirrhosis | Cancer
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2014, Volume 62, Issue 1, pp. 24 - 30
Journal Article